Lansforsakringar Fondforvaltning AB publ Lowers Stock Holdings in Pfizer Inc. $PFE

Lansforsakringar Fondforvaltning AB publ lowered its position in Pfizer Inc. (NYSE:PFE) by 12.8% during the 3rd quarter, Holdings Channel reports. The firm owned 2,893,108 shares of the biopharmaceutical company’s stock after selling 426,228 shares during the quarter. Lansforsakringar Fondforvaltning AB publ’s holdings in Pfizer were worth $73,716,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of PFE. Vanguard Group Inc. lifted its stake in shares of Pfizer by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after purchasing an additional 10,198,330 shares during the last quarter. Geode Capital Management LLC increased its stake in Pfizer by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock valued at $3,080,552,000 after purchasing an additional 1,820,634 shares in the last quarter. Norges Bank purchased a new position in Pfizer in the 2nd quarter worth $2,270,157,000. Charles Schwab Investment Management Inc. raised its stake in shares of Pfizer by 2.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock worth $1,191,760,000 after purchasing an additional 1,135,457 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its stake in Pfizer by 2.0% during the 2nd quarter. Fisher Asset Management LLC now owns 48,390,268 shares of the biopharmaceutical company’s stock valued at $1,172,980,000 after acquiring an additional 950,239 shares during the period. Institutional investors own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Erste Group nudged up its FY2026 and FY2027 EPS estimates (to $2.97 and $2.84 respectively), a modest improvement to street forecasts that supports earnings visibility. Erste Group estimate lift
• Positive Sentiment: Pfizer announced positive results from its BREAKWATER trial — a near-term pipeline win that can underpin future revenue and investor confidence if it advances toward approval/commercialization. Pfizer BREAKWATER trial results
• Positive Sentiment: Several bullish retail-focused pieces highlight Pfizer’s ~6% dividend yield, stable cash flows and defensive profile as reasons it could be a value/dividend play during market volatility. Those narratives support demand from income-focused investors. Massive News: Pfizer’s 6% Dividend Could Be Safer Than You Think
• Neutral Sentiment: Comparisons with AstraZeneca highlight that Pfizer trades cheaper and pays a higher yield, but AZN’s stronger growth targets temper PFE’s relative upside — useful context for allocation decisions. AstraZeneca vs. Pfizer
• Neutral Sentiment: Lists of high-dividend, low-volatility stocks include Pfizer, reinforcing its role as a defensive, income-oriented holding for some portfolios. 10 High Dividend Stocks With Low Volatility
• Negative Sentiment: Barclays initiated coverage with an underweight call, signaling fresh sell-side skepticism that can pressure the stock if other firms follow suit. Barclays initiates coverage with underweight
• Negative Sentiment: Critical commentaries warn that Pfizer’s ~6% yield carries risks (cash-flow pressure, payout sustainability, and valuation traps), fueling investor caution on dividend reliability. Pfizer: A Risky 6.3% Yield
• Negative Sentiment: Other analyst initiations noted in the press include bearish starts, adding to near-term sentiment pressure for the stock. Bearish analyst initiations

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Barclays assumed coverage on Pfizer in a report on Thursday. They issued an “underweight” rating and a $25.00 price objective for the company. UBS Group began coverage on Pfizer in a research note on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price objective for the company. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. TD Cowen reiterated a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $27.84.

Pfizer Price Performance

Pfizer stock opened at $26.66 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.94. The firm has a market cap of $151.55 billion, a PE ratio of 19.60 and a beta of 0.47. The company’s 50 day moving average is $25.95 and its two-hundred day moving average is $25.31.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the previous year, the firm posted $0.63 earnings per share. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.5%. Pfizer’s dividend payout ratio is 126.47%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.